Modulation of GSK-3 as a therapeutic strategy on tau pathologies

Frontiers in Molecular Neuroscience

Volumn 4, Issue , 2011, Pages

  Medina, Miguel ^a   Garrido, Juan Jose ^b   Wandosell, Francisco G ^b,c  

^a Research Department   (Spain)

^b CSIC   (Spain)

^c CENTRO DE BIOLOGÍA MOLECULAR SEVERO OCHOA   (Spain)

Author keywords

Alzheimer; GSK 3; Kinases modulation; Tau pathologies

Indexed keywords

AZD 1080; GLYCOGEN SYNTHASE KINASE 3; GLYCOGEN SYNTHASE KINASE 3 INHIBITOR; LITHIUM; MULTIPROTEIN COMPLEX; TIDEGLUSIB; UNCLASSIFIED DRUG; VALPROIC ACID;

ALZHEIMER DISEASE; CELLULAR DISTRIBUTION; CLINICAL TRIAL (TOPIC); COGNITIVE DEFECT; DISEASE MODEL; DRUG TARGETING; ENZYME ACTIVITY; ENZYME LOCALIZATION; ENZYME PHOSPHORYLATION; ENZYME REGULATION; ENZYME SPECIFICITY; FRONTOTEMPORAL DEMENTIA; HUMAN; MULTICENTER STUDY (TOPIC); NEUROLOGIC DISEASE; NONHUMAN; PHASE 2 CLINICAL TRIAL (TOPIC); PROGRESSIVE SUPRANUCLEAR PALSY; PROTEIN AGGREGATION; PROTEIN CLEAVAGE; PROTEIN EXPRESSION; RANDOMIZED CONTROLLED TRIAL (TOPIC); REVIEW; TAUOPATHY;

EID: 84856619287     PISSN: 16625099     EISSN: None     Source Type: Journal    
DOI: 10.3389/fnmol.2011.00024     Document Type: Review

References (141)

1. Aberle, H., Bauer, A., Stappert, J., Kispert, A., and Kemler, R. (1997). beta-catenin is a target for the ubiquitin-proteasome pathway. EMBOJ. 16,3797-3804.
2. Alessi, D. R., Caudwell, F. B., And-jelkovic, M., Hemmings, B. A., and Cohen, P. (1996). Molecular basis for the substrate specificity of protein kinase B; comparison with MAPKAP kinase-1 and p70 S6 kinase. FEBS Lett. 399, 333-338.
3. Alonso Adel, C., Li, B., Grundke-Iqbal, I., and Iqbal, K. (2006). Polymerization of hyperphosphorylated tau into filaments eliminates its inhibitory activity. Proc. Natl. Acad. Sci. U.S.A. 103, 8864-8869.
4. Alvarez, G., Munoz-Montano, J. R., Satrustegui, J., Avila, J., Bogonez, E., and Diaz-Nido, J. (1999). Lithium protects cultured neurons against beta-amyloid-induced neurodegeneration. FEBS Lett. 453, 260-264.
5. Amit, S., Hatzubai, A., Birman, Y., Andersen, J. S., Ben-Shushan, E., Mann, M., Ben-Neriah, Y., and Alka-lay, I. (2002). Axin-mediated CKI phosphorylation of beta-catenin at Ser 45: a molecular switch for the Wnt pathway. Genes Dev. 16, 1066-1076.
6. Avila, J., Lucas, J. J., Perez, M., and Hernandez, F. (2004). Role of tau protein inboth physiological andpatho-logical conditions. Physiol. Rev. 84, 361-384.
7. Ayuso-Mateos, J.L., Vazquez-Barquero, J.L., Dowrick, C., Lehtinen, V., Dal-gard, O. S., Casey, P., Wilkinson, C., Lasa, L., Page, H., Dunn, G., and Wilkinson, G. (2001). Depressive disorders in Europe: prevalence figures from the ODIN study. Br. J. Psychiatry 179, 308-316.
8. Ballatore, C., Lee, V. M., and Tro-Janowski, J. Q. (2007).Tau-mediated neurodegeneration in Alzheimer’s disease and related disorders. Nat. Rev. Neurosci. 8, 663-672.
9. Beaulieu, J. M., Gainetdinov, R. R., and Caron, M. G. (2009). Akt/GSK3 signaling in the action of psychotropic drugs. Annu. Rev. Pharmacol. Toxicol. 49, 327-347.
10. Bhat, R. V., Shanley, J., Correll, M. P., Fieles, W. E., Keith, R. A., Scott, C. W., and Lee, C. M. (2000). Regulation and localization of tyrosine216 phosphorylation of glycogen synthase kinase-3beta in cellular and animal models of neuronal degeneration. Proc. Natl. Acad. Sci. U.S.A. 97, 11074-11079.
11. Bijur, G. N., and Jope, R. S. (2003). Glycogen synthase kinase-3 beta is highly activated in nuclei and mitochondria. Neuroreport 14, 2415-2419.
12. Buee, L., Bussiere, T., Buee-Scherrer, V., Delacourte, A., and Hof, P. R. (2000). Tau protein isoforms, phosphorylation and role in neurodegenerative disorders. Brain Res. Brain Res. Rev. 33, 95-130.
13. Caccamo, A., Oddo, S., Tran, L. X., and LaFerla, F. M. (2007). Lithium reduces tau phosphorylation but not A beta or working memory deficits in a transgenic model with both plaques and tangles. Am. J. Pathol. 170, 1669-1675.
14. Cardona-Gomez, P., Perez, M., Avila, J., Garcia-Segura, L. M., and Wan-dosell, F. (2004). Estradiol inhibits GSK3 and regulates interaction of estrogen receptors, GSK3, and beta-catenin in the hippocampus. Mol. Cell. Neurosci. 25, 363-373.
15. Castano, Z., Gordon-Weeks, P., and Kypta, R. (2010). The neuron-specific isoform of GSK-3b2 is required for axon growth. J. Neu-rochem. 113, 117-130.
16. Chou, H. Y., Howng, S. L., Cheng, T. S., Hsiao, Y. L., Lieu, A. S., Loh, J. K., Hwang, S. L., Lin, C. C., Hsu, C. M., Wang, C., Lee, C. I., Lu, P. J., Chou, C. K., Huang, C. Y., and Hong, Y. R. (2006). GSKIP is homologous to the Axin GSK3beta interaction domain and functions as a negative regulator of GSK3beta. Biochemistry 45, 11379-11389.
17. Chun, J., Goetzl, E. J., Hla, T., Igarashi, Y., Lynch, K. R., Moolenaar, W., Pyne, S., and Tigyi, G. (2002). International Union of Pharmacology. XXXIV. Lysophospholipid receptor nomenclature. Pharmacol. Rev. 54, 265-269.
18. Cohen, P. (1999). The Croonian Lecture 1998. Identification ofaprotein kinase cascade of major importance in insulin signal transduction. Philos. Trans. R. Soc. Lond. B Biol. Sci. 354, 485-495.
19. Cohen, P., and Frame, S. (2001). The renaissance of GSK3. Nat. Rev. Mol. CellBiol. 2,769-776.
20. Cole, A., Frame, S., and Cohen, P. (2004). Further evidence that the tyrosine phosphorylation of glycogen synthase kinase-3 (GSK3) in mammalian cells is an autophosphorylation event. Biochem. J. 377, 249-255.
21. Cross, D. A., Alessi, D. R., Cohen, P., Andjelkovich, M., and Hemmings, B. A. (1995). Inhibition of glycogen synthase kinase-3 by insulin mediated byprotein kinase B. Nature 378, 785-789.
22. Dajani, R., Fraser, E., Roe, S. M., Young, N., Good, V., Dale, T. C., and Pearl, L. H. (2001). Crystal structure of glycogen synthase kinase 3 beta: structural basis for phosphate-primed substrate specificity and autoinhibition. Cell 105, 721-732.
23. De Sarno, P., Bijur, G. N., Zmijew-ska, A. A., Li, X., and Jope, R. S. (2006). In vivo regulation of GSK3 phosphorylation by cholinergic and NMDA receptors. Neurobiol. Aging 27,413-422.
24. del Puerto, A., Diaz-Hernandez, J.-I., Tapia, M., Benitez, M. J., Zhang, J., Diaz-Hernandez, M., Wandosell, F., and Garrido, J.-J. (2011). Adenylate cyclase 5 coordinates the action of ADP, P2Y1, P2Y13, and ATP-gated P2 x 7 receptors on axonal elongation. J. Cell Sci. (in press).
25. Del Rio, J. A., Gonzalez-Billault, C., Urena, J. M., Jimenez, E. M., Bar-allobre, M. J., Pascual, M., Pujadas, L., Simo, S., La Torre, A., Wandosell, F., Avila, J., and Soriano, E. (2004). MAP1B is required for Netrin 1 signaling in neuronal migration and axonal guidance. Curr. Biol. 14, 840-850.
26. Delarasse, C., Auger, R., Gonnord, P., Fontaine, B., and Kanellopoulos, J. M. (2010). The purinergic receptor P2 x 7 triggers alpha-secretase-dependent processing of the amyloid precursor protein. J. Biol. Chem. 286, 2596-2606.
27. Delcommenne, M., Tan, C., Gray, V., Rue, L., Woodgett, J., and Ded-har, S. (1998). Phosphoinositide-3-OH kinase-dependent regulation of glycogen synthase kinase 3 and protein kinase B/AKT by the integrin-linked kinase. Proc. Natl. Acad. Sci. U.S.A. 95, 11211-11216.
28. Diaz-Hernandez, M., del Puerto, A., Diaz-Hernandez, J. I., Diez-Zaera, M., Lucas, J. J., Garrido, J. J., and Miras-Portugal, M. T. (2008). Inhibition of the ATP-gated P2 x 7 receptor promotes axonal growth and branching in cultured hippocampal neurons. J. Cell. Sci. 121, 3717-3728.
29. Ding, Q., Xia, W., Liu, J. C., Yang, J. Y., Lee, D. F., Xia, J., Bartholomeusz, G., Li, Y., Pan, Y., Li, Z., Bargou, R. C., Qin, J., Lai, C. C., Tsai, F. J., Tsai, C. H., and Hung, M. C. (2005). Erk associates with and primes GSK-3beta for its inactivation resulting in upregulation of beta-catenin. Mol. Cell 19, 159-170.
30. Eickholt, B. J., Walsh, F. S., and Doherty, P. (2002). An inactive pool of GSK-3 at the leading edge of growth cones is implicated in Semaphorin 3A signaling. J. Cell Biol. 157, 211-217.
31. Engel, T., Goni-Oliver, P., Gomez de Barreda, E., Lucas, J. J., Hernandez, F., and Avila, J. (2008). Lithium, a potential protective drug in Alzheimer’s disease. Neurode-gener. Dis. 5, 247-249.
32. Engel, T., Goni-Oliver, P., Lucas, J. J., Avila, J., and Hernandez, F. (2006a). Chronic lithium administration to FTDP-17 tau and GSK-3beta overexpressing mice prevents tau hyperphosphorylation and neurofibrillary tangle formation, but pre-formed neurofibrillarytangles do not revert. J. Neurochem. 99, 1445-1455.
33. Engel, T., Hernandez, F., Avila, J., and Lucas, J. J. (2006b). Full reversal of Alzheimer’s disease-like phenotype in a mouse model with conditional overexpression of glycogen synthase kinase-3. J. Neurosci. 26, 5083-5090.
34. Fang, X., Yu, S. X., Lu, Y., Bast, R. C. Jr., Woodgett, J. R., and Mills, G. B. (2000). Phosphorylation and inactivation of glycogen synthase kinase 3 by protein kinaseA. Proc. Natl. Acad. Sci. U.S.A. 97, 11960-11965.
35. Ferkey, D. M., and Kimelman, D. (2002). Glycogen synthase kinase-3 beta mutagenesis identifies a common binding domain for GBP and Axin. J. Biol. Chem. 277, 16147-16152.
36. Forleza, O., Diniz, B., Radanovic, M., Santos, F., Talib, L., and Gattaz, W. (2011). Disease-modifying properties of long-term lithium treatment for amnesic milsd cognitive impair-ment:randomised controlled trial. Br. J. Psychol. 198,351-356.
37. Frame, S., and Cohen, P. (2001). GSK3 takes centre stage more than 20 years after its discovery. Biochem. J. 359, 1-16.
38. Frame, S., Cohen, P., and Biondi, R. M. (2001).Acommon phosphate binding site explains the unique substrate specificity of GSK3 and its inactivation by phosphorylation. Mol. Cell 7, 1321-1327.
39. Fraser, E., Young, N., Dajani, R., Franca-Koh, J., Ryves, J., Williams, R. S., Yeo, M., Webster, M. T., Richardson, C., Smalley, M. J., Pearl, L. H., Harwood, A., and Dale, T. C. (2002). Identification of the Axin and Frat binding region of glycogen synthase kinase-3. J. Biol. Chem. 277,2176-2185.
40. Gadakar, P., Phukan, S., Dattatreya, P., and Balaji, V. (2007). Pose prediction accuracy in docking studies and enrichment of actives in the active site of GSK-3beta. J. Chem. Inf. Model. 47, 446-459.
41. Garrido, J. J., Simon, D., Varea, O., and Wandosell, F. (2007). GSK3 alpha and GSK3 beta are necessary for axon formation. FEBS Lett. 581, 1579-1586.
42. Gong, C. X., Singh, T. J., Grundke-Iqbal, I., and Iqbal, K. (1993). Phos-phoprotein phosphatase activities in Alzheimer disease brain. J. Neu-rochem. 61, 921-927.
43. Goni-Oliver, P., Lucas, J. J., Avila, J., and Hernandez, F. (2007). N-terminal cleavage of GSK-3 by calpain: a new form of GSK-3 regulation. J. Biol. Chem. 282,22406-22413.
44. Gonzalez-Billault, C., Del Rio, J. A., Urena, J. M., Jimenez-Mateos, E. M., Barallobre, M. J., Pascual, M., Pujadas, L., Simo, S., Torre, A. L., Gavin, R., Wandosell, F., Soriano, E., and Avila, J. (2005). A role of MAP1B in Reelin-dependent neuronal migration. Cereb. Cortex 15, 1134-1145.
45. Gould, T., and Manji, H. (2006). “Glyco-gen synthase kinase 3: a target for novel mood disorder treatments," Chapter 7, in Glycogen Synthase Kinase 3 (GSK-3) and its Inhibitors-Drug Discovery and Development, ed. B. Wang (New Jersey, NJ: Wiley), 125-154.
46. Gould, T. D., and Manji, H. K. (2002). The Wnt signaling pathway in bipolar disorder. Neuroscientist 8, 497-511.
47. Grimes, C. A., and Jope, R. S. (2001). The multifaceted roles of glycogen synthase kinase 3beta in cellular signaling. Prog. Neurobiol. 65, 391-426.
48. Hampel, H., Ewers, M., Burger, K., Annas, P., Mortberg, A., Bogst-edt, A., Frolich, L., Schroder, J., Schonknecht, P., Riepe, M. W., Kraft, I., Gasser, T., Leyhe, T., Moller, H. J., Kurz, A., and Basun, H. (2009). Lithium trial in Alzheimer’s disease: a randomized, single-blind, placebo-controlled, multicenter 10-week study. J. Clin. Psychiatry 70, 922-931.
49. Hanger, D. P., Hughes, K., Woodgett, J. R., Brion, J. P., and Anderton, B. H. (1992). Glycogen synthase kinase-3 induces Alzheimer’s disease-like phosphorylation of tau: generation of paired helical filament epitopes and neuronal localisation of the kinase. Neurosci. Lett. 147, 58-62.
50. Harr, S. D., Hollister, R. D., and Hyman, B. T. (1996). Glycogen synthase kinase 3 alpha and 3 beta do not colocalize with neurofibrillary tangles. Neurobiol. Aging 17, 343-348.
51. Hart, M. J., de los Santos, R., Albert, I. N., Rubinfeld, B., and Polakis, P. (1998). Downregulation of beta-catenin by human Axin and its association with the APC tumor suppressor, beta-catenin and GSK3 beta. Curr. Biol. 8, 573-581.
52. Hartigan, J. A., Xiong, W. C., and Johnson, G. V. (2001). Glycogen synthase kinase 3beta is tyrosine phosphorylated by PYK2. Biochem. Biophys. Res. Commun. 284, 485-489.
53. Harwood, A. J. (2001). Regulation of GSK-3: a cellular multiprocessor. Cell 105,821-824.
54. Havens, W. W. II, and Cole. J. (1982). Successful treatment of dementia with lithium. J. Clin. Psychopharma-col. 2, 71-72.
55. Hernandez, F., and Avila, J. (2008). Tau aggregates and tau pathology. J. Alzheimers Dis. 14, 449-452.
56. Hernandez, F., de Barreda, E. G., Fuster-Matanzo, A., Goni-Oliver, P., Lucas, J. J., and Avila, J. (2009). The role of GSK3 in Alzheimer disease. Brain Res. Bull. 80, 248-250.
57. Hoover, B. R., Reed, M. N., Su, J., Penrod, R. D., Kotilinek, L. A., Grant, M. K., Pitstick, R., Carlson, G. A., Lanier, L. M., Yuan, L. L., Ashe, K. H., and Liao, D. (2010). Tau mislocal-ization to dendritic spines mediates synaptic dysfunction independently of neurodegeneration. Neuron 68, 1067-1081.
58. Hye, A., Kerr, F., Archer, N., Foy, C., Poppe, M., Brown, R., Hamilton, G., Powell, J., Anderton, B., and Love-stone, S. (2005). Glycogen synthase kinase-3 is increased in white cells early in Alzheimer’s disease. Neu-rosci. Lett. 373, 1-4.
59. Ishiguro, K., Shiratsuchi, A., Sato, S., Omori, A., Arioka, M., Kobayashi, S., Uchida, T., and Imahori, K. (1993). Glycogen synthase kinase 3 beta is identical to tau protein kinase I generating several epitopes of paired helical filaments. FEBS Lett. 325, 167-172.
60. Itoh, K., Tang, T. L., Neel, B. G., and Sokol, S. Y. (1995). Specific modulation of ectodermal cell fates in Xenopus embryos by glycogen synthase kinase. Development 121, 3979-3988.
61. Kaidanovich-Beilin, O., and Eldar-Finkelman, H. (2006). Long-term treatment with novel glycogen synthase kinase-3 inhibitor improves glucose homeostasis in ob/ob mice: molecular characterization in liver and muscle. J. Pharmacol. Exp. Ther. 316, 17-24.
62. Kandasamy, A. D., and Schulz, R. (2009). Glycogen synthase kinase-3beta is activated by matrix metalloproteinase-2 mediated proteolysis in cardiomyoblasts. Cardiovasc. Res. 83, 698-706.
63. Kim, L., Harwood, A., and Kimmel, A. R. (2002). Receptor-dependent and tyrosine phosphatase-mediated inhibition of GSK3 regulates cell fate choice. Dev. Cell 3, 523-532.
64. Kim, L., Liu, J., and Kimmel, A. R. (1999). The novel tyrosine kinase ZAK1 activates GSK3 to direct cell fate specification. Cell 99, 399-408.
65. Klein, P. S., and Melton, D. A. (1996). A molecular mechanism for the effect of lithium on development. Proc. Natl. Acad. Sci. U.S.A. 93, 8455-8459.
66. Lesort, M., Jope, R. S., and Johnson, G. V. (1999). Insulin transiently increases tau phosphorylation: involvement of glycogen synthase kinase-3beta and Fyn tyrosine kinase. J. Neurochem. 72, 576-584.
67. Lezoualc’h, F. (2007). 5-HT4 receptor and Alzheimer’s disease: the amyloid connection. Exp. Neurol. 205, 325-329.
68. Li, L., Yuan, H., Weaver, C. D., Mao, J., Farr, G. H. III, Sussman, D. J., Jonkers, J., Kimelman, D., and Wu, D. (1999). Axin and Frat1 interact with dvl and GSK, bridging Dvl to GSK in Wnt-mediated regulation of LEF-1. EMBO J. 18, 4233-4240.
69. Li, X., Bijur, G. N., and Jope, R. S. (2002). Glycogen synthase kinase-3beta, mood stabilizers, and neuroprotection. Bipolar Disord. 4, 137-144.
70. Liu, F., Gong, X., Zhang, G., Marquis, K., Reinhart, P., and Andree, T. H. (2005). The inhibition of glycogen synthase kinase 3beta by a metabotropic glutamate receptor 5 mediated pathway confers neuroprotection to Abeta peptides. J. Neurochem. 95, 1363-1372.
71. Liu, S. J., Zhang, A. H., Li, H. L., Wang, Q., Deng, H. M., Netzer, W. J., Xu, H., andWang, J. Z. (2003). Overactivation of glycogen synthase kinase-3 by inhibition of phosphoinositol-3 kinase and protein kinase C leads to hyperphosphorylation of tau and impairment of spatial memory. J. Neurochem. 87, 1333-1344.
72. Lovestone, S., Reynolds, C. H., Latimer, D., Davis, D. R., Anderton, B. H., Gallo, J. M., Hanger, D., Mulot, S., Marquardt, B., Stabel, S., Woodgett, J. R., and Miller, C. C. J. (1994). Alzheimer’s disease-like phosphorylation of the microtubule-associated protein tau by glycogen synthase kinase-3 in transfected mammalian cells. Curr. Biol. 4, 1077-1086.
73. Lucas, F. R., and Salinas, P. C. (1997). WNT-7a induces axonal remodeling and increases synapsin I levels in cerebellar neurons. Dev. Biol. 192, 31-44.
74. Lucas, J. J., Hernandez, F., Gomez-Ramos, P., Moran, M. A., Hen, R., and Avila, J. (2001a). Decreased nuclear beta-catenin, tau hyperphosphorylation and neurodegeneration in GSK-3beta conditional transgenic mice. EMBO J. 20, 27-39.
75. Lucas, J. J., Hernandez, F., Gomez-Ramos, P., Moran, M. A., Hen, R., and Avila, J. (2001b). Decreased nuclear beta-catenin, tau hyperphosphorylation and neurodegeneration in GSK-3beta conditional transgenic mice. EMBO J. 20, 27-39.
76. Macdonald, A., Briggs, K., Poppe, M., Higgins, A., Velayudhan, L., and Lovestone, S. (2008). A feasibility and tolerability study of lithium in Alzheimer’s disease. Int. J. Geriatr. Psychiatry 23, 704-711.
77. Mangialasche, F., Solomon, A., Winblad, B., Mecocci, P., and Kivipelto, M. (2010). Alzheimer’s disease: clinical trials and drug development. Lancet Neurol. 9,702-716.
78. Mao, Y., Ge, X., Frank, C. L., Madison, J. M., Koehler, A. N., Doud, M. K., Tassa, C., Berry, E. M., Soda, T., Singh, K. K., Biechele, T., Petryshen, T. L., Moon, R. T., Haggarty, S. J., and Tsai, L. H. (2009). Disrupted in schizophrenia 1 regulates neuronal progenitor proliferation via modulation of GSK3beta/beta-catenin signaling. Cell 136, 1017-1031.
79. Martin, C. P., Vazquez, J., Avila, J., and Moreno, F. J. (2002). P24, a glycogen synthase kinase 3 (GSK 3) inhibitor. Biochim. Biophys. Acta 1586, 113-122.
80. Meares, G. P., Mines, M. A., Beurel, E., Eom, T. Y., Song, L., Zmijew-ska, A. A., and Jope, R. S. (2011). Glycogen synthase kinase-3 regulates endoplasmic reticulum (ER) stress-induced CHOP expression in neuronal cells. Exp. Cell Res. 317, 1621-1628.
81. Medina, M., and Avila, J. (2010). Glycogen synthase kinase-3 (GSK-3) inhibitors for the treatment of Alzheimer’s disease. Curr. Pharm. Des. 16, 2790-2798.
82. Medina, M., and Castro, A. (2008). Glycogen synthase kinase-3 (GSK-3) inhibitors reach the clinic. Curr. Opin. Drug Discov. Dev. 11, 533-543.
83. Medina, M., and Wandosell, F. (2011). Deconstructing GSK-3: the fine regulation of its activity. Int. J. Alzheimers Dis. 2011, 479249.
84. Mendez, P., Azcoitia, I., and Garcia-Segura, L. M. (2005). Interdependence of oestrogen and insulinlike growth factor-I in the brain: potential for analysing neuroprotec-tive mechanisms. J. Endocrinol. 185, 11-17.
85. Moon, R. T., Kohn, A. D., De Ferrari, G. V., and Kaykas, A. (2004). WNT and beta-catenin signalling: diseases and therapies. Nat. Rev. Genet. 5, 691-701.
86. Mukai, F., Ishiguro, K., Sano, Y., and Fujita, S. C. (2002). Alternative splicing isoform of tau protein kinase I/glycogen synthase kinase 3beta. J. Neurochem. 81, 1073-1083.
87. Munoz-Montano, J. R., Moreno, F. J., Avila, J., and Diaz-Nido, J. (1997). Lithium inhibits Alzheimer’s disease-like tau protein phosphorylation in neurons. FEBS Lett. 411, 183-188.
88. Nakashima, H., Ishihara, T., Suguimoto, P., Yokota, O., Oshima, E., Kugo, A., Terada, S., Hamamura, T., Tro-janowski, J. Q., Lee, V. M., and Kuroda, S. (2005). Chronic lithium treatment decreases tau lesions by promoting ubiquitination in a mouse model of tauopathies. Acta Neuropathol. 110, 547-556.
89. Nishimura, I., Yang, Y., and Lu, B. (2004). PAR-1 kinase plays an initiator role in a temporally ordered phosphorylation process that confers tau toxicity in Drosophila. Cell 116, 671-682.
90. Noble, W., Olm, V., Takata, K., Casey, E., Mary, O., Meyerson, J., Gaynor, K., La Francois, J., Wang, L., Kondo, T., Davies, P., Burns, M., Veeranna Nixon, R., Dickson, D., Matsuoka, Y., Ahlijanian, M., Lau, L. F., and Duff, K. (2003). Cdk5 is a key factor in tau aggregation and tangle formation in vivo. Neuron 38, 555-565.
91. Noble, W., Planel, E., Zehr, C., Olm, V., Meyerson, J., Suleman, F., Gaynor, K., Wang, L., LaFrancois, J., Fein-stein, B., Burns, M., Krishnamurthy, P., Wen, Y., Bhat, R., Lewis, J., Dickson, D., and Duff, K. (2005). Inhibition of glycogen synthase kinase-3 by lithium correlates with reduced tauopathy and degeneration in vivo. Proc. Natl. Acad. Sci. U.S.A. 102, 6990-6995.
92. Pap, M., and Cooper, G. M. (1998). Role of glycogen synthase kinase-3 in the phosphatidylinositol 3- Kinase/Akt cell survival pathway. J. Biol. Chem. 273, 19929-19932.
93. Patel, D. S., Dessalew, N., Iqbal, P., and Bharatam, P. V. (2007). Structure-based approaches in the design of GSK-3 selective inhibitors. Curr. Protein Pept. Sci. 8, 352-364.
94. Pawlak, V., and Kerr, J. N. (2008). Dopamine receptor activation is required for corticostriatal spike-timing-dependent plasticity. J. Neu-rosci. 28, 2435-2446.
95. Pei, J. J., Tanaka, T., Tung, Y. C., Braak, E., Iqbal, K., and Grundke-Iqbal, I. (1997). Distribution, levels, and activity of glycogen synthase kinase-3 in the Alzheimer disease brain. J. Neuropathol. Exp. Neurol. 56, 70-78.
96. Peineau, S., Taghibiglou, C., Bradley, C., Wong, T. P., Liu, L., Lu, J., Lo, E., Wu, D., Saule, E., Bouschet, T., Matthews, P., Isaac, J. T., Bor-tolotto, Z. A., Wang, Y. T., and Collingridge, G. L. (2007). LTP inhibits LTD in the hippocampus via regulation of GSK3beta. Neuron 53, 703-717.
97. Perez, M., Hernandez, F., Lim, F., Diaz-Nido, J., and Avila, J. (2003a). Chronic lithium treatment decreases mutant tau protein aggregation in a transgenic mouse model. J. Alzheimers Dis. 5, 301-308.
98. Perez, M., Rojo, A. I., Wandosell, F., Diaz-Nido, J., and Avila, J. (2003b). Prion peptide induces neuronal cell death through a pathway involving glycogen synthase kinase 3. Biochem. J. 372, 129-136.
99. Phiel, C. J., Wilson, C. A., Lee, V. M., and Klein, P. S. (2003). GSK-3alpharegu-lates production of Alzheimer’s disease amyloid-beta peptides. Nature 423, 435-439.
100. Piedrahita, D., Hernandez, I., Lopez-Tobon, A., Fedorov, D., Obara, B., Manjunath, B. S., Boudreau, R. L., Davidson, B., Laferla, F., Gallego-Gomez, J. C., Kosik, K. S., and Cardona-Gomez, G. P. (2010). Silencing of CDK5 reduces neurofibrillary tangles in transgenic Alzheimer’s mice. J. Neurosci. 30, 13966-13976.
101. Plotkin, B., Kaidanovich, O., Talior, I., and Eldar-Finkelman, H. (2003). Insulin mimetic action of synthetic phosphorylated peptide inhibitors of glycogen synthase kinase-3. J. Pharmacol. Exp. Ther. 305, 974-980.
102. Rahman, A., Grundke-Iqbal, I., and Iqbal, K. (2005). Phosphothreonine-212 of Alzheimer abnormally hyper-phosphorylated tau is a preferred substrate of protein phosphatase-1. Neurochem. Res. 30, 277-287.
103. Ray, W. J. Jr., Szymanki, E. S., and Ng, L. (1978). The binding of lithium and of anionic metabolites to phospho-glucomutase. Biochim. Biophys. Acta 522, 434-442.
104. Rosso, S. B., Sussman, D., Wynshaw-Boris, A., and Salinas, P. C. (2005). Wnt signaling through Dishevelled, Rac and JNK regulates dendritic development. Nat. Neurosci. 8, 34-42.
105. Rowe, M. K., Wiest, C., and Chuang, D. M. (2007). GSK-3 is a viable potential target for therapeutic intervention in bipolar disorder. Neurosci. Biobehav. Rev. 31, 920-931.
106. Ruel, L., Bourouis, M., Heitzler, P., Pan-tesco, V., and Simpson, P. (1993). Drosophila shaggy kinase and rat glycogen synthase kinase-3 have conserved activities and act downstream of Notch. Nature 362, 557-560.
107. Rylatt, D. B., Aitken, A., Bilham, T., Condon, G. D., Embi, N., and Cohen, P. (1980). Glycogen synthase from rabbit skeletal muscle. Amino acid sequence at the sites phosphorylated by glycogen synthase kinase-3, and extension of the N-terminal sequence containing the site phosphorylated by phosphory-lase kinase. Eur. J. Biochem. 107, 529-537.
108. Sanz, J. M., Chiozzi, P., Ferrari, D., Cola-ianna, M., Idzko, M., Falzoni, S., Fellin, R., Trabace, L., and Di Virgilio, F. (2009). Activation of microglia by amyloid {beta} requires P2 x 7 receptor expression. J. Immunol. 182, 4378-4385.
109. Sayas, C. L., Avila, J., and Wan-dosell, F. (2002). Regulation of neuronal cytoskeleton by lysophospha-tidic acid: role of GSK-3. Biochim. Biophys. Acta 1582,144-153.
110. Sayas, C. L., Moreno-Flores, M. T., Avila, J., and Wandosell, F. (1999). The neurite retraction induced by lysophosphatidic acid increases Alzheimer’s disease-like Tau phosphorylation. J. Biol. Chem. 274, 37046-37052.
111. Schaffer, B., Wiedau-Pazos, M., and Geschwind, D. H. (2003). Gene structure and alternative splicing of glycogen synthase kinase 3 beta (GSK-3beta) in neural and non-neural tissues. Gene 302, 73-81.
112. Sengupta, A., Wu, Q., Grundke-Iqbal, I., Iqbal, K., and Singh, T. J. (1997). Potentiation of GSK-3-catalyzed Alzheimer-like phosphorylation of human tau by cdk5. Mol. Cell. Biochem. 167, 99-105.
113. Shaldubina, A., Agam, G., and Bel-maker, R. H. (2001). The mechanism of lithium action: state of the art, ten years later. Prog. Neuropsy-chopharmacol. Biol. Psychiatry 25, 855-866.
114. Shi, S. H., Cheng, T., Jan, L. Y., and Jan, Y. N. (2004). APC and GSK-3beta are involved in mPar3 targeting to the nascent axon and establishment of neuronal polarity. Curr. Biol. 14, 2025-2032.
115. Simon, D., Benitez, M. J., Gimenez-Cassina, A., Garrido, J. J., Bhat, R. V., Diaz-Nido, J., and Wandosell, F. (2008). Pharmacological inhibition of GSK-3 is not strictly correlated with a decrease in tyrosine phosphorylation of residues 216/279. J. Neurosci. Res. 86, 668-674.
116. Simon, D., Medina, M., Avila, J., and Wandosell, F. (2011). Overcoming cell death and tau phosphorylation mediated by PI3K-inhibition: a cell assay to measure neuroprotection. CNSNeurol. Disord. DrugTargets 10, 208-214.
117. Smillie, K. J., and Cousin, M. A. (2011). The role of GSK3 in presynap-tic function. Int. J. Alzheimers Dis. 263-673.
118. Soutar, M. P., Kim, W. Y., Williamson, R., Peggie, M., Hastie, C. J., H. McLauchlan, Snider, W. D., Gordon-Weeks, P. R., and Sutherland, C. (2010). Evidence that glycogen synthase kinase-3 isoforms have distinct substrate preference in the brain. J. Neurochem. 115,974-983.
119. Stambolic, V., and Woodgett, J. R. (1994). Mitogen inactivation of glycogen synthase kinase-3 beta in intact cells via serine 9 phosphorylation. Biochem. J. 303(Pt 3), 701-704.
120. Stoothoff, W. H., Cho, J. H., McDonald, R. P., and Johnson, G. V. (2005). FRAT-2 preferentially increases glycogen synthase kinase 3 beta-mediated phosphorylation of primed sites, which results in enhanced tau phosphorylation. J. Biol. Chem. 280, 270-276.
121. Sutherland, C., Leighton, I. A., and Cohen, P. (1993). Inactivation of glycogen synthase kinase-3 beta by phosphorylation: new kinase connections in insulin and growth-factor signalling. Biochem. J. 296, 15-19.
122. Swatton, J. E., Sellers, L. A., Faull, R. L., Holland, A., Iritani, S., and Bahn, S. (2004). Increased MAP kinase activity in Alzheimer’s and Down syndrome but not in schizophrenia human brain. Eur. J. Neurosci. 19, 2711-2719.
123. Takahashi, M., Tomizawa, K., Kato, R., Sato, K., Uchida, T., Fujita, S. C., and Imahori, K. (1994). Localization and developmental changes of tau protein kinase I/glycogen synthase kinase-3 beta in rat brain. J. Neurochem. 63, 245-255.
124. Takashima, A., Honda, T., Yasutake, K., Michel, G., Murayama, O., Murayama, M., Ishiguro, K., and Yamaguchi, H. (1998). Activation of tau protein kinase I/glycogen synthase kinase-3beta by amyloid beta peptide (25-35) enhances phosphorylation of tau in hippocampal neurons. Neurosci. Res. 31, 317-323.
125. Ter Haar, E. (2006). “The crystal structure of glycogen synthase kinase 3," Chapter 5, in Glycogen Synthase Kinase 3 (GSK-3) and its Inhibitors-DrugDiscovery and Development, ed. B. Wang (New Jersey, NJ: Wiley), 61-82.
126. ter Haar, E., Coll, J. T., Austen, D. A., Hsiao, H. M., Swenson, L., and Jain, J. (2001). Structure of GSK3beta reveals a primed phosphorylation mechanism. Nat. Struct. Biol. 8, 593-596.
127. Terao, T., Nakano, H., Inoue, Y., Okamoto, T., Nakamura, J., and Iwata, N. (2006). Lithium and dementia: a preliminary study. Prog. Neuropsychopharmacol. Biol. Psychiatry 30, 1125-1128.
128. Thornton, T. M., Pedraza-Alva, G., Deng, B., Wood, C. D., Aronsh-tam, A., Clements, J. L., Sabio, G., Davis, R. J., Matthews, D. E., Doble, B., and Rincon, M. (2008). Phosphorylation by p38 MAPK as an alternative pathway for GSK3beta inactivation. Science 320, 667-670.
129. Tigyi, G., Fischer, D. J., Sebok, A., Marshall, F., Dyer, D. L., and Miledi, R. (1996). Lysophos-phatidic acid-induced neurite retraction in PC12 cells: neurite-protective effects of cyclic AMP signaling. J. Neurochem. 66, 549-558.
130. Trojanowski, J. Q., and Lee, V.M. (2005). Pathological tau: a loss of normal function or a gain in toxicity? Nat. Neurosci. 8, 1136-1137.
131. Twomey, C., and McCarthy, J. V. (2006). Presenilin-1 is an unprimed glycogen synthase kinase-3beta substrate. FEBSLett. 580,4015-4020.
132. Varea, O., Garrido, J. J., Dopazo, A., Mendez, P., Garcia-Segura, L. M., and Wandosell, F. (2009). Estradiol activates beta-catenin dependent transcription in neurons. PLoS ONE 4, e5153. doi: 10.1371/jour-nal.pone.0005153
133. Wang, Q. M., Fiol, C. J., DePaoli-Roach, A. A., and Roach, P. J. (1994). Glycogen synthase kinase-3 beta is a dual specificity kinase differentially regulated by tyrosine and serine/threonine phosphorylation. J. Biol. Chem. 269, 14566-14574.
134. Wang, X., Arcuino, G., Takano, T., Lin, J., Peng, W. G., Wan, P., Li, P., Xu, Q., Liu, Q. S., Goldman, S. A., and Ned-ergaard, M. (2004). P2 x 7 receptor inhibition improves recovery after spinal cord injury. Nat. Med. 10, 821-827.
135. Watcharasit, P., Bijur, G. N., Zmijew-ski, J. W., Song, L., Zmijewska, A., Chen, X., Johnson, G. V., and Jope, R. S. (2002). Direct, activating interaction between glycogen synthase kinase-3beta and p53 after DNA damage. Proc. Natl. Acad. Sci. U.S.A. 99, 7951-7955.
136. Woodgett, J. R. (1990). Molecular cloning and expression of glycogen synthase kinase-3/factorA. EMBO J. 9, 2431-2438.
137. Xu, C., Kim, N. G., and Gumbiner, B. M. (2009). Regulation of protein stability by GSK3 mediated phosphorylation. Cell Cycle 8, 4032-4039.
138. York, J. D., Ponder, J. W., and Majerus, P. W. (1995). Definition of a metal-dependent/Li(+)-inhibited phosphomonoesterase protein family based upon a conserved three-dimensional core structure. Proc. Natl. Acad. Sci. U.S.A. 92, 5149-5153.
139. Yost, C., Farr, G. H. III, Pierce, S. B., Fer-key, D. M., Chen, M. M., and Kimel-Man, D. (1998). GBP, an inhibitor of GSK-3, is implicated in Xenopus development and oncogenesis. Cell 93, 1031-1041.
140. Yu, Y., Run, X., Liang, Z., Li, Y., Liu, F., Liu, Y., Iqbal, K., Grundke-Iqbal, I., and Gong, C. X. (2009). Developmental regulation of tau phosphorylation, tau kinases, and tau phosphatases. J. Neurochem. 108, 1480-1494.
141. Zhou, F. Q., Zhou, J., Dedhar, S., Wu, Y. H., and Snider, W. D. (2004). NGF-induced axon growth is mediated by localized inactivation of GSK-3beta and functions of the microtubule plus end binding protein APC. Neuron 42, 897-912.